DFTX
Definium Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C-
Company Profile
CEO
Robert Barrow
IPO Date
2016-11-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Definium Therapeutics, Inc.
CEO
Robert Barrow
IPO Date
2016-11-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 3,013 |
| $45.03 |
| 26 Jun 2026 | Barrow Robert | director, officer: Chief Executive Officer | S-Sale | Disposed | 29,208 | $45.03 |
| 26 Jun 2026 | Karlin Daniel | Chief Medical Officer | S-Sale | Disposed | 10,035 | $45.03 |
| 26 Jun 2026 | Wiley Matthew T. | Chief Commercial Officer | S-Sale | Disposed | 2,867 | $45.03 |
| 22 Jun 2026 | Wiley Matthew T. | Chief Commercial Officer | A-Award | Acquired | 62,500 | $0.00 |
| 22 Jun 2026 | Barrow Robert | director, officer: Chief Executive Officer | A-Award | Acquired | 375,000 | $0.00 |
| 22 Jun 2026 | Roberts Brandi | Chief Financial Officer | A-Award | Acquired | 62,500 | $0.00 |
| 22 Jun 2026 | Sullivan Mark | Chief Legal Officer | A-Award | Acquired | 62,500 | $0.00 |
| 22 Jun 2026 | Karlin Daniel | Chief Medical Officer | A-Award | Acquired | 100,000 | $0.00 |